John Sagartz, DVM, PhD, DACVP, Director, Basis Global Technologies Inc.
John Sagrtz is President of Seventh Wave Laboratories LLC, a biopharmaceutical manufacturing company that offers (bio)analytical, in vivo toxicology and molecular pathology services for preclinical drug metabolism within the pharmaceutical industry.
He holds a Ph.D in Economics from Florida State University, and his research products have earned professional awards and been published in academic/industry journals. Furthermore, his government experience includes serving as policy analyst for FHFA on affordable housing programs and property insurance issues.
John Sagrtz has more than 15 years of experience in the biotechnology industry. He began as a toxicologic pathologist at Searle/Monsanto in 1996 and held positions of increasing responsibility until Monsanto’s merger with Pharmacia in 2003. Later, he founded Seventh Wave Laboratories where he served as President & Chief Executive Officer as well as Chief Strategy Officer until BASi acquired them in July 2018; following which, he joined their Board of Directors to help guide operations while offering broader solutions and scientific expertise to clients.
Internships offer students a valuable learning experience, helping them hone skills that will be valuable in the workplace. Furthermore, internships serve to foster professional connections and create a talent pipeline for future employers.
Achievements and Honors
John Sagartz, DVM, PhD, DACVP was an esteemed pathologist with a remarkable professional career in both academia and industry. As the founder and chief executive officer of Seventh Wave Laboratories, he led a team that pioneered novel technologies in biomedicine. Later as Chief Strategy Officer for Inotiv he helped define their future plans while serving as Chief Strategy Officer. Among Sagartz’ many accolades he was named a Distinguished Service Award winner in affordable housing programs as well as being part of the Federal Reserve Bank of New York’s triennial Survey of Consumer Finances.
John Sagartz is a Chief Strategy Officer and Director at Basis Global Technologies Inc. He owns 634,232 shares of the company’s stock, with two insider trades since 2019. Most recently, on August 19, 2020 John Sagartz purchased 3,733 units of BASI stock worth $17,732 worth of securities.
John Sagartz has an estimated net worth of $3.01M. Since November 2018, he has served as Chief Strategy Officer at Inotiv, a company providing (bio)analytical, in vivo toxicology and molecular pathology services for preclinical drug metabolism in drug development. Prior to that he founded Seventh Wave Laboratories which was acquired by BASi in July 2018. Earlier on John served as Policy Analyst at New York City Department of Housing Preservation and Development’s Office of Policy and Strategy where he monitored and reported on affordable housing programs as well as NYC’s housing lottery system.
John Sagartz has an estimated net worth of $10.4 million. He serves as Chief Strategy Officer at Inotiv, Inc., a pharmaceutical development company. Inotiv offers drug discovery, development services and analytical instruments; its Research Services segment conducts screening tests, pharmacological testing, preclinical safety studies, formulation development, regulatory compliance services and quality control testing – plus they manufacture vivo sampling systems/accessories, physiology monitoring tools/liquid chromatography platforms plus electrochemistry instruments as well.
Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996 and quickly rose through the ranks to positions of increasing responsibility such as section head, director, preclinical development site head, and fellow. Following Monsanto’s merger with Pharmacia he co-founded Seventh Wave Laboratories where he served as president & chief executive officer as well as chief strategy officer.